Using CAR T cells to treat children with hard-to-treat solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 clinical trial evaluates the safety and early efficacy of CAR T cells engineered to target the B7-H3 antigen in children with solid tumors that have relapsed or are unresponsive to standard treatments. The study focuses on pediatric patients aged 1 to 25 years who have measurable B7-H3 positive solid tumors. Participants will receive B7H3-IL7Ra CAR-T cells after undergoing leukapheresis, and their response to the treatment will be monitored. This innovative approach aims to provide a new therapeutic option for a population with limited treatment alternatives.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants must have B7-H3 positive solid tumor with measurable disease.

   \- B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) or flow cytometry using a previously obtained sample.
2. Evidence of relapsed or refractory disease after standard first-line therapy
3. Age 1 - 25 years
4. Sex: Male or female
5. Performance status: Lansky or Karnofsky score not less than 50
6. Life expectancy not less than 12 weeks
7. Normal organ function

   * AST (SGOT) below 5 times the upper limit of normal (ULN)
   * ALT (SGPT) below 5 times the upper limit of normal (ULN)
   * Total bilirubin below 3 times the upper limit of normal (ULN)
   * Creatinine below 5 times the upper limit of normal (ULN)
   * SpO2 room air not less than 90%
8. Prior therapy wash-out before planned leukapheresis

   * Not less than 7 days post last chemotherapy/biologic therapy administration
   * 3 half-lives or 30 days, whichever is shorter after the last dose of antitumor antibody therapy
   * At least 30 days from most recent cellular infusion
   * All systemically administered corticosteroid treatment therapy must be stable or decreasing within 1 week prior to enrollment with a maximum of 0.5 mg/kg/day dose of methylprednisolone. Corticosteroid physiologic replacement therapy is allowed
9. Participants and/or legal guardians must have the ability to understand and willingness to sign a written informed consent and/or assent document

Exclusion Criteria:

1. Presence of greater than or equal to grade 3 cardiac dysfunction or symptomatic arrythmia requiring intervention
2. Presence of primary immunodeficiency or bone marrow failure syndrome
3. Presence of uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities, or psychiatric illness/social situations that would limit compliance with study requirements
4. Pregnant or breastfeeding women were excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. Participants of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment in this study and for four months after receiving CAR-T-cell infusion.
5. Serologic status reflecting active HIV, hepatitis B or C infection. Participants who are positive for hepatitis B core antibody, hepatitis B surface antigen or hepatitis C antibody must have negative PCR prior to enrollment.

Where it's running

• King Chulalongkorn Memorial Hospital
  Bangkok, Pathumwan, Thailand Recruiting

Study contacts

• Principal investigator: Piti Techavichit, Associate Professor, MD — Chulalongkorn University
• Study coordinator: Piti Techavichit, Associate Professor, MD
• Email: Piti.T@chula.ac.th
• Phone: +66817515363

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults

  This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07915102

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• CD19 CAR-T Therapy for Kids with Refractory Childhood SLE

  This study tests whether a patient’s own CD19 CAR-T cells can help children and young adults with severe, hard-to-treat lupus.

  Recruiting Phase 1 Seoul National University Hospital · Seoul · NCT07855302

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• CAR-T Cell Therapy for B-ALL (relapsed/refractory)

  This trial tests a patient’s own CAR-T cells to treat relapsed or refractory B-cell ALL in people aged 5–50.

  Recruiting Early Phase 1 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi · NCT07695012

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.